Pabau Engage inbox

Pabau Engage is here: every patient conversation in one inbox.

Learn more
Book a demo Book a demo
☰
HCPCS Code

HCPCS code J2507 – Pegloticase injection


Code Definition

J2507 is the HCPCS Level II code for injection, pegloticase, 1 mg. It reports the drug only, at one unit per milligram, so a standard 8 mg Krystexxa infusion bills as 8 units.

Pegloticase is sold as Krystexxa, manufactured by Horizon Therapeutics, a wholly owned Amgen subsidiary since October 2023. It treats chronic gout in adults that has not responded to conventional therapy, and the infusion itself is billed separately with CPT 96365 and 96366.

Level
Level II
Category
J — Drugs administered other than oral method
Code range
J0120-J8999 Drugs administered other than oral method (non-chemotherapy)
Billable
No
Code also known as
Krystexxa, pegloticase infusion, pegloticase biologic, gout biologic injection
Save time. Improve accuracy. Get paid faster.
Automate coding with Pabau

Let Pabau's smart automation suggest the right codes, reduce claim denials, and keep your practice compliant—effortlessly.

  • AI-powered code suggestions
  • Real-time compliance checks
  • Faster claims, fewer denials
Why practices choose Pabau
Save hours every week

Automate repetitive tasks and focus on what matters most—your patients.

Improve accuracy

Reduce coding errors and ensure compliance with the latest regulations.

Get paid faster

Clean claims, fewer denials, and faster reimbursements.

Grow with confidence

Powerful insights and reporting to help your practice thrive.

HIPAA compliant SOC 2 certified GDPR-compliant Trusted by 4,000+ clinics worldwide

Key takeaways

Key takeaways

HCPCS code J2507 reports pegloticase (Krystexxa) per 1 mg, for chronic gout in adults that has not responded to conventional therapy.

The standard 8 mg dose bills as 8 units of J2507, and the 120-minute infusion adds CPT 96365 and 96366 on their own lines.

Medicare has required the JW or JZ modifier on J2507 since July 1, 2023, and returns claims without one as unprocessable.

Most payers require prior authorization, usually with documented failure of both allopurinol and febuxostat.

Pabau, our practice management platform, tracks each authorization’s code, dates and sessions, and sends claims through the Claim.MD clearinghouse.

HCPCS code J2507: Code descriptor and drug overview

HCPCS code J2507 is the Level II J-code for injection, pegloticase, 1 mg. It replaced the temporary code C9281 on January 1, 2012, as CMS Transmittal 2378 records. The code identifies the drug itself, not the administration service.

Pegloticase is a recombinant uricase enzyme that converts uric acid to allantoin, which the kidneys excrete easily. The FDA approves it only for chronic gout in adults that is refractory to conventional therapy.

In practice, the disease has not responded to xanthine oxidase inhibitors such as allopurinol and febuxostat. That narrow indication shapes the medical necessity documentation and the prior authorization request.

FieldDetail
HCPCS codeJ2507
Official descriptorInjection, pegloticase, 1 mg
Drug namePegloticase
Brand nameKrystexxa, manufactured by Horizon Therapeutics, a wholly owned Amgen subsidiary since October 2023
Drug classRecombinant uricase (pegylated)
FDA indicationChronic refractory gout in adults
Billing categoryHCPCS Level II, J-code (drug infusion)
Payment modelBuy-and-bill; Medicare Part B ASP+6%

J2507 unit calculation: How to bill pegloticase correctly

J2507 is billed per 1 mg of pegloticase. The FDA-approved dose for Krystexxa is 8 mg administered as an IV infusion every two weeks. Each infusion therefore requires 8 units of J2507 on the claim line.

Under- or over-reporting units is one of the top audit triggers for J-code biologics. Billing 1 unit instead of 8 recovers only 12.5% of the drug cost. Billing 9 or more units for a standard dose doesn’t match the 8 mg vial, and payers flag that mismatch for overpayment review.

Dose administeredUnits to bill (J2507)Notes
8 mg (standard)8 unitsFDA-approved dose; most claims
Drug wastage present8 units administered + JW modifier for discarded amountReport actual dose + wastage separately
No wastage8 units + JZ modifierMandatory for dates of service on or after July 1, 2023 (CMS policy)

NDC reporting requirements for J2507

Most Medicaid programs and many commercial payers require the 11-digit National Drug Code (NDC) reported alongside J2507. Failure to include a valid NDC is among the leading denial reasons for this code.

The NDC must be submitted in the correct 5-4-2 format (manufacturer-product-package), using the N4 qualifier on the claim. Report the actual NDC from the vial dispensed, not a generic crosswalk number. The unit of measure and quantity fields must be completed too.

For Krystexxa, the unit of measure is ML, and the quantity is the volume used from the vial. Krystexxa now ships in two single-dose vials, 8 mg/mL and a ready-to-use 8 mg/50 mL, so the quantity depends on which one you opened.

NDC fieldRequirement
Format11-digit, 5-4-2 (no dashes on electronic claims)
QualifierN4 (loop 2410, segment LIN or CTP)
Unit of measureML (milliliter)
QuantityVolume of drug administered from the vial
SourceVial label dispensed on date of service

Medicare does not require NDC reporting for Part B claims submitted on the CMS-1500. Medicaid state plans and commercial payers set their own rules, so check each one before submission.

Companion CPT codes for infusion administration

J2507 covers only the drug. The infusion administration service is billed separately using CPT codes from the therapeutic infusion series. Submit each code on its own claim line.

  • CPT 96365: Intravenous infusion for therapy, initial, up to 1 hour. This is the primary administration code for a Krystexxa infusion.
  • CPT 96366: Each additional hour of the same infusion. An additional hour counts once the infusion runs more than 30 minutes past the previous hour.
  • CPT 96375 or 96367 for pre-medications: The label calls for antihistamines and corticosteroids before each infusion. A pre-medication given by IV push is reported with 96375, and one given as its own infusion with 96367. Oral pre-medications carry no administration code, and the payer’s bundling edits still apply.

Krystexxa is infused over no less than 120 minutes, according to its prescribing information. A standard visit with no IV pre-medication therefore bills J2507 × 8 units on line 1 and 96365 × 1 unit on line 2.

CPT 96366 × 1 unit follows on line 3 for the second hour. The chart below lays out those three lines and what each one needs before submission.

Claim lines for one standard 8 mg Krystexxa infusion
A 120-minute Krystexxa infusion produces three claim lines, and only the drug line carries the NDC and the JZ modifier. Figures from the Krystexxa label and CMS MLN Matters MM13056.

Pro Tip

Always verify that J2507 and the administration CPT code are on separate claim lines with separate revenue codes in facility billing. Combining them into a single line is a common formatting error that triggers an automatic edit rejection before the claim even reaches a human reviewer.

ICD-10 diagnosis codes that support J2507

J2507 requires a supported ICD-10 diagnosis code on every claim. The diagnosis must reflect the indication for pegloticase, which is chronic refractory gout in an adult who has failed conventional therapy. Linking J2507 to an unsupported code triggers an automatic medical necessity denial.

ICD-10 codeDescriptionSupported?
M10.00Idiopathic gout, unspecified siteYes
M10.01-M10.09Idiopathic gout, specified joint sitesYes
M10.9Gout, unspecifiedYes (less specific; document accordingly)
M1A codesChronic gout (with or without tophus)Yes – preferred for refractory/tophaceous disease
M11.1x, M11.2x, E79.0Calcium pyrophosphate deposition (familial or other chondrocalcinosis); hyperuricemia without goutNo – not an approved indication for pegloticase

Many payers also want chart notes showing that allopurinol and febuxostat each failed at the maximum tolerated dose, for at least three months. Those notes should point back to the diagnosis code, because the chart carries the medical necessity case as much as the code does. A claim coded to M10.9 is supportable, but the chart then has to supply the detail the code leaves out.

Medicare reimbursement: ASP pricing and site of service

Medicare Part B reimburses J2507 at the drug’s Average Sales Price plus 6% (ASP+6%), as established under the Medicare Prescription Drug, Improvement, and Modernization Act.

CMS publishes updated ASP-based allowables each quarter, so the per-unit rate for J2507 changes four times a year. Check the current quarter’s rate in the CMS ASP pricing files before quoting expected reimbursement.

Site of service affects the actual payment a practice receives. In a physician office, Medicare pays ASP+6% directly to the billing provider under the buy-and-bill model. In a hospital outpatient department, the drug is reimbursed under the outpatient prospective payment system (OPPS) at a different rate. Ambulatory surgical centers may not cover J2507 at all, depending on their carve-out status.

SettingPayment methodologyNotes
Physician officeASP+6% (Part B drug benefit)Buy-and-bill; practice acquires and bills the drug
Hospital outpatientOPPS APC rateRate differs from ASP+6%; facility bills separately
Infusion center (non-HOD)ASP+6% if Medicare-enrolledVerify enrollment status and Part B coverage

Prior authorization requirements for J2507 (Krystexxa)

Prior authorization for J2507 is required by Medicare Advantage plans, all Medicaid managed care programs, and virtually every major commercial payer. Traditional Medicare fee-for-service does not require prior authorization for J2507, but Medicare Advantage plans operate under their own criteria.

Typical prior authorization criteria across major payers include:

  • A confirmed diagnosis of chronic refractory gout, with ICD-10 documentation
  • Documented failure of allopurinol at the maximum tolerated dose for at least three months
  • Documented failure of febuxostat at the maximum tolerated dose, and at some payers a probenecid trial as well
  • A baseline serum uric acid level above the payer’s threshold, commonly 6 mg/dL
  • A qualified prescriber, usually a rheumatologist

Payer criteria for J2507 change often. Check each payer’s current clinical policy bulletin before you submit, then work through these steps.

  • Step 1: Confirm the patient’s payer and plan type. Medicare Advantage and Medicaid managed care plans have the most stringent criteria.
  • Step 2: Gather chart documentation of prior therapy failure, uric acid levels, and specialist notes.
  • Step 3: Submit the PA request through the payer portal or via phone/fax, attaching the treating physician’s attestation.
  • Step 4: Track the authorization number, effective dates, and quantity limits. PA approvals for Krystexxa often include a dose count limit or infusion count ceiling.
  • Step 5: Re-verify authorization before each infusion visit. Expired or quantity-exceeded authorizations cause denials even when the original PA was approved.

Common J2507 claim denials and how to appeal them

J2507 has an above-average denial rate among biologic J-codes, and most of those denials are preventable. The table below maps the most frequent denial reasons to their remark codes and corrective actions.

Denial reasonCommon remark codeCorrective action
Missing or invalid NDCCO-4, N382Resubmit with correct 11-digit NDC, N4 qualifier, ML unit, and quantity
Missing or expired prior authCO-15, CO-197Obtain retro-authorization (if payer allows) or appeal with PA documentation
Medical necessity not establishedCO-50, N115Appeal with chart notes documenting prior therapy failure and uric acid levels
Incorrect unit countCO-4, CO-11Correct units to match dose administered (8 units for standard 8 mg dose) and resubmit
Missing JW or JZ modifierCO-4, CO-16Add appropriate modifier per CMS MLN Matters MM13056 guidance and resubmit
Diagnosis code mismatchCO-50, MA130Verify ICD-10 supports pegloticase indication; correct to M10 or M1A series
Non-covered settingCO-58, CO-96Confirm site-of-service eligibility with payer; transfer administration to covered setting

Effective denial management workflows for J2507 start at scheduling. Build a pre-claim checklist into infusion booking, so the PA number, NDC, unit count and modifier are settled well before billing day. Our guide to remittance advice denial codes defines each CARC in the table above.

Pro Tip

Run a pre-submission eligibility check the day before each Krystexxa infusion. Verify that the PA is active, the authorization number on file matches the payer’s system, and the remaining authorized dose count covers the upcoming infusion. Catching a lapsed PA the day before saves a denial, a retro-auth request, and a potential delayed treatment.

JW and JZ modifier rules for J2507

CMS requires the JW or JZ modifier on every J2507 claim line for dates of service on or after July 1, 2023. Voluntary JZ reporting began on January 1, 2023, and the July date made it mandatory. Since October 1, 2023, Medicare has returned claims that lack either modifier as unprocessable. Many commercial payers have adopted the same policy.

  • JW modifier (Drug Amount Discarded/Not Administered to Any Patient): Use when a portion of the vial is discarded after administering the dose. Report the discarded amount as a separate J2507 line item with the JW modifier. Only discarded drug from a single-use vial qualifies; drug from multi-use vials does not.
  • JZ modifier (Zero Drug Wastage): Use when the entire vial content is administered with no drug discarded. This is a positive attestation that wastage reporting is not required. Without JZ (or JW), the claim is incomplete under MLN Matters MM13056 guidance.

Incorrect modifier application carries compliance risk. Billing JW for wastage that did not occur can trigger an Office of Inspector General audit, and so can a missing JZ attestation. Document the vial configuration and actual volume administered in the administration record on every infusion date.

Documentation checklist for J2507 billing compliance

This checklist pulls every required element into one pre-submission review for each J2507 claim. Run it as part of your medical billing compliance routine. New billing staff can start with how medical billing works before taking on infusion claims.

  • Prior authorization confirmed: Active PA on file, authorization number recorded, effective date covers date of service, dose count not exceeded.
  • ICD-10 code verified: M10 or M1A code matches chart diagnosis; prior therapy failure documented in chart notes.
  • NDC field complete: 11-digit NDC from dispensed vial, N4 qualifier, ML unit of measure, volume quantity, where the payer requires it.
  • Unit count accurate: J2507 units = mg administered (8 units for standard 8 mg dose); unit count matches administration record.
  • Modifier applied: JW (wastage present) or JZ (zero wastage) on every J2507 claim line.
  • Administration CPT codes on separate lines: CPT 96365 and 96366 each on their own claim line, correctly sequenced.
  • Provider credentials verified: Treating provider is enrolled with the payer and specialty matches coverage criteria (rheumatology).
  • Eligibility confirmed: Patient’s payer coverage active on date of service; Part B active for Medicare patients.

A clean claim for J2507 is one where every item on this list was verified before the claim left the practice.

How claims management software keeps J2507 claims clean

Many J2507 denials begin before the claim exists. An authorization lapses between infusions, or its infusion count runs out, and nobody sees it until the remittance comes back.

Pabau is the practice management platform we build. Its claims management software holds the authorization code, dates and sessions on the patient’s case. Staff get a warning when an authorization is missing, so the lapse surfaces at booking.

Claims then go out through the Claim.MD clearinghouse as CMS-1500/837P claims, with eligibility checked before the visit. ERA remittances post back to the same record, so a missing JZ rejection shows up against the visit it belongs to. IV sessions record the drug’s lot number against the patient and the appointment as well.

Pabau billing screen showing claims integrated with the patient record
Pabau’s billing view keeps each J2507 claim beside its authorization and remittance, so a rejection traces straight back to the visit.

Reduce J2507 claim denials before they happen

Pabau tracks each prior authorization’s code, dates and sessions on the patient’s case, and submits claims through the Claim.MD clearinghouse. See how it handles a biologic infusion claim from booking to remittance.

Pabau claims management dashboard

Conclusion

J2507 claims are won or lost at the booking desk. Confirm the authorization window, the vial and its NDC, and the modifier when the infusion goes on the calendar. Then check them once more at billing.

Krystexxa repeats every two weeks, so one lapsed authorization can put several infusions at risk before anyone notices. Book a demo to see how Pabau tracks authorizations and sends infusion claims from the same patient record.

Continue your research

Continue your research

Need a clearinghouse that handles HCPCS J-code claims? Medical claims clearinghouse guide explains how clearinghouses validate HCPCS codes before claims reach payers.

Looking to understand remittance advice better? Electronic remittance advice (ERA) explained covers how to read ERAs and match denial codes to J2507 rejections.

Want to benchmark your billing performance? Best medical billing software for US practices compares platforms that support specialty drug billing workflows.

Building the prior authorization request? The prior authorization process walks through each step from payer criteria to approval.

Need a form for the payer submission? Medical prior authorization form gives you a ready template for the clinical details payers ask for.

Frequently asked questions

What does HCPCS code J2507 cover?

HCPCS code J2507 covers pegloticase injection, billed per 1 mg. Pegloticase treats chronic gout in adults that has not responded to conventional uric acid-lowering therapy such as allopurinol or febuxostat. It identifies the drug only; infusion administration is billed separately using CPT 96365 and 96366.

How many units do I bill for J2507?

Bill 8 units of J2507 for each standard Krystexxa infusion, because the FDA-approved dose is 8 mg and J2507 is billed per 1 mg. If the administered dose differs from 8 mg, bill the actual number of milligrams administered.

What is the Medicare reimbursement rate for J2507?

Medicare Part B reimburses J2507 at ASP+6% (Average Sales Price plus 6%), updated quarterly by CMS. The per-unit rate changes each quarter; check the current CMS quarterly drug pricing file before quoting expected reimbursement, as the figures shift with market pricing.

Does J2507 require prior authorization?

Yes, prior authorization is required by Medicare Advantage plans, Medicaid managed care programs, and virtually all major commercial payers for J2507. Traditional Medicare fee-for-service does not require prior authorization, but most patients receiving Krystexxa are covered under plans that do.

What NDC number should be reported with J2507?

Report the 11-digit NDC from the Krystexxa vial dispensed on the date of service, with the N4 qualifier. Use ML as the unit of measure and the volume administered as the quantity. Do not use a generic crosswalk NDC; always pull the number from the specific vial label used for that patient encounter.

What are common denial reasons for J2507 claims?

The most frequent J2507 denials are a missing or invalid NDC (CO-4, N382) and an absent or expired prior authorization (CO-15, CO-197). Unestablished medical necessity (CO-50), an incorrect unit count (CO-11) and a missing JW or JZ modifier follow. Missing NDC and lapsed prior authorizations together account for the majority of preventable denials on this code.

Avatar photo
Anja Dodevska
Content Writer

Anja Dodevska writes about healthcare, dermatology, and the day-to-day realities of running a medical practice for Pabau. She enjoys breaking down complex topics into clear, accessible content and has a soft spot for the often-overlooked aspects of clinic life. When she's not writing, she's exploring cafes, walking her dog, or spending time with friends and family.
×